SUM159PT Xenograft Model Service for Breast Cancer

The SUM159PT xenograft model provides a highly aggressive, mesenchymal-like in vivo translational platform specifically optimized for validating candidate novel targeted therapies, anti-metastatic compounds, and CSC inhibitors in refractory TNBC. Alfa Cytology delivers a comprehensive, end-to-end SUM159PT xenograft model service, blending fully authenticated claudin-low molecular assets with standardized procedural imaging and sampling to accelerate preclinical oncology drug discovery timelines.

Overview of SUM159PT Xenograft Model for Breast Cancer

The SUM159PT cell line is a highly specialized and aggressive human mammary carcinoma model widely used in preclinical oncology to investigate TNBC heterogeneity, epithelial-mesenchymal transition (EMT), and tumor-initiating cell biology. Originally isolated from a primary anaplastic carcinoma of the breast from a patient with locally advanced disease, this model is molecularly classified within the claudin-low or mesenchymal-like subtype of TNBC. It is phenotypically defined by the absolute absence of ER, PR, and HER2 expression. Crucially, SUM159PT possesses a unique and powerful oncogenic signature characterized by key driving mutations, including an activating mutation in the HRAS gene (G12D) alongside a hotspot mutation in the PIK3CA gene (H1047R). This specific co-activation of the MAPK and PI3K/Akt/mTOR signaling axes bypasses normal growth constraints and renders the model exceptionally useful for evaluating small-molecule kinase inhibitors, combination therapies targeting parallel pathways, and agents designed to disrupt metabolic reprogramming in stubborn tumors.

When established in vivo as a xenograft in immunocompromised mice, SUM159PT cells develop into fast-growing, poorly differentiated mesenchymal solid tumors that closely mimic the hyper-invasive kinetics, rapid angiogenesis, and spontaneous macrometastasis to secondary visceral organs observed in clinical metastatic TNBC patients.

Cell Line Information: SUM159PT

The SUM159PT cell line maintains a distinct spindle-like, mesenchymal morphology in vitro and reliably preserves its signature HRAS/PIK3CA mutations, stem-like features, and triple-negative status upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the SUM159PT Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including CSC frequency analysis and PK/PD profiling. Leveraging our expertise in mesenchymal-like/claudin-low TNBC models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of SUM159PT Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the SUM159PT xenograft model:

• Cell Culture & Quality Control: SUM159PT cells are cultivated in specialized, serum-supplemented growth media enriched with insulin and hydrocortisone under optimal atmospheric parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Selection & Acclimatization: Standardized immunocompromised mice (such as BALB/c Nude or NOD/SCID strains) are selected based on specific study requirements and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability SUM159PT cells is prepared and blended with a verified biological basement membrane matrix carrier to optimize spatial cell attachment and mimic the aggressive stroma. The mixture is precisely injected in vivo via orthotopic mammary fat pad or subcutaneous routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. SUM159PT Xenograft Model Construction Workflow

Case Study - SUM159PT Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the SUM159PT xenograft model was successfully utilized to evaluate the therapeutic efficacy and synergetic interaction of a novel small-molecule dual PI3K/mTOR inhibitor when combined with a selective MEK blocker. Under optimized modeling conditions and precise matrix-assisted orthotopic inoculation protocols, our technical team achieved highly reproducible tumor engraftment and uniform growth curves across all immunodeficient cohorts, enabling an unobstructed and definitive assessment of target inhibition.

Our Advantages

Choosing the right partner for your aggressive, mesenchymal-like triple-negative breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable HRAS and PIK3CA dual driving mutations and validated claudin-low features.
• Technical Consistency: Optimized inoculation protocols utilizing customized matrix support to ensure uniform tumor growth and minimize variance across study cohorts.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, cancer stem cell (CSC) frequency analysis, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research and animal welfare standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, mesenchymal-like triple-negative breast cancer or target CSC-driven resistance pathways using the robust SUM159PT xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.